CGEM Cullinan Therapeutics
- 16.770
- -0.600-3.45%
- 16.770
- 0.0000.00%
Cullinan Therapeutics News
Cullinan Therapeutics | 8-K: Current report
Cullinan Therapeutics | 8-K: Current report
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Michaelson Jennifer
Cullinan Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Cullinan Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Thistle Mary
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Thistle Mary
Cullinan Therapeutics | 10-Q: Q2 2024 Earnings Report
Cullinan Therapeutics | 8-K: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Michaelson Jennifer
Cullinan Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Michaelson Jennifer
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Webster Stephen W
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rosenberg Anthony
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Martin Anne-Marie
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ryan David P.
Cullinan Therapeutics | 8-K: Current report
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ebeling Thomas
Cullinan Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.8%)
Cullinan Therapeutics | EFFECT: Others
Cullinan Therapeutics | 424B3: Prospectus
Analysis
Price Target
No Data
No Data